Zantel

Quick links to important sections

Zantel

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zantel

Zantel is a fixed-dose combination product containing the synthetic active substances Fenbendazole and Praziquantel, and it is classified as a broad-spectrum anthelmintic. This drug entity is a specialized antiparasitic agent primarily utilized in the veterinary use context to manage parasitic worm infections in animals.


Quick Facts

Property Description
Active Ingredients Fenbendazole, Praziquantel
Form Oral Tablet
Pharmacological Class Broad-spectrum anthelmintic
General Purpose Clearance of parasitic worms (nematodes and cestodes)
Origin Synthetic Compounds

What Type of Medicine is Zantel? (Identity and Classification)

Zantel is an oral tablet that belongs to the pharmacological class of broad-spectrum anthelmintics, defined by its composition of two distinct, synthetic chemical entities. The active ingredient Fenbendazole is classified as a Benzimidazole derivative, a chemical group used to combat parasites. The second component, Praziquantel, is a Pyrazinoisoquinoline derivative. This combination product means the host receives a single, standardized dose of both agents, which are delivered via the oral route of administration to achieve systemic effects against internal parasites. Unlike monotherapy drugs, the dual-agent formulation is typically clinically recognized for providing enhanced efficacy against both major classes of parasitic infection.


What is the General Purpose of the Fenbendazole-Praziquantel Combination? (Synergy and Benefit)

The fundamental purpose of the Fenbendazole and Praziquantel combination is to achieve highly comprehensive clearance against a broad range of parasitic worms in the host. This combination is effective because it targets two major parasite groups: cestodes (tapeworms) and gastrointestinal nematodes (roundworms). Fenbendazole works by interfering with the worm's ability to absorb nutrients, while Praziquantel causes rapid muscle paralysis. By integrating these two distinct mechanisms, the combination maximizes the therapeutic benefit by addressing the full spectrum of helminthiasis often found in mixed infections, offering a reliable, comprehensive treatment solution. There is a recognized strategic advantage to such combinations for the management of both roundworms and tapeworms simultaneously. This provides a single, efficient treatment option, for instance, in the routine deworming of domestic animals where mixed infections are common.

Regulatory References

  1. MedlinePlus

What side effects are possible with Zantel?

Possible Side Effects and Safety Information

The official safety profile for the Fenbendazole-Praziquantel combination is structured by regulatory bodies to categorize and communicate potential adverse reactions and usage constraints. This section provides an overview of the safety information documented in government sources.


Adverse Reaction Scope

Category Description
Key Adverse Reactions Gastrointestinal disturbances (such as vomiting, diarrhea, and inappetence) and transient systemic or Nervous System manifestations (like lethargy and restlessness) are the key adverse reactions listed.
Frequency Classification Adverse effects are generally classified as Very Rare (less than 1 in 10,000 treated) in regulatory documents under recommended conditions of use.
System-Organ Classes The effects are primarily categorized under Gastrointestinal Disorders and Nervous System Disorders. Hypersensitivity responses are tracked under Immune System Disorders.
Serious Adverse Reactions Serious events like hypersensitivity reactions are documented through post-market surveillance. Furthermore, bone marrow hypoplasia has been reported in association with the extra-label use of the Fenbendazole component for prolonged durations.

Safety Constraints and Considerations

The product is contraindicated in animals with a known hypersensitivity to Praziquantel, Fenbendazole, or any of its inactive ingredients, as specified in official labeling. Population-specific safety notes advise that the product is generally not recommended during pregnancy in some species due to a lack of complete data. Use is also contraindicated in very young animals (e.g., puppies or kittens less than three weeks old) in certain formulations. Safety documentation also highlights that serious reactions, such as blood disorders, are specifically linked to the practice of using the active ingredients beyond the specified labeled treatment duration.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Zantel (albendazole) involves taking amounts significantly greater than prescribed, leading to an exaggeration of the drug's known adverse effects. Because of the potential for serious consequences, any suspected overdose requires immediate professional medical attention.

Documented Signs and Symptoms of Overdose

Official regulatory information indicates that acute overdose may manifest as pronounced gastrointestinal distress, including nausea, vomiting, and diarrhea. More serious documented outcomes following exposure to very high doses include signs of systemic toxicity affecting the blood and liver. Specific severe manifestations noted in regulatory documents are:

  • Pancytopenia: A significant decrease in all types of blood cells.
  • Transaminase Elevation: Increased levels of liver enzymes, indicating potential liver toxicity.
  • Alopecia: Hair loss.

Required Emergency Actions

When to Seek Immediate Medical Help:

You must contact a Poison Information Centre or seek emergency medical care immediately if you suspect or know that you or someone else has taken a large amount of Zantel. This action is necessary even if there are no immediate visible signs of discomfort or poisoning.

Overdose Management

Management of a Zantel overdose is described in official labeling as being symptomatic and supportive. This means healthcare professionals will treat the specific symptoms the patient develops while providing support for vital functions. No specific chemical antidote is currently documented in official regulatory materials.

Therapeutic Uses of Zantel

What Zantel Treats: Main Uses and Benefits

The product is relevant in contexts that require a comprehensive anthelmintic approach for managing mixed infections, and may assist with managing certain distressing symptoms associated with internal parasites. This medication is applied in addressing the symptomatic burden of helminthiasis, which is commonly used to help with conditions involving cestodes (tapeworms) and various nematodes (roundworms).

The product is commonly used for managing symptoms related to systemic imbalance and gastrointestinal distress that may appear suddenly or fluctuate due to a parasitic burden. This may assist with managing issues that interfere with daily comfort, such as chronic diarrhea, vomiting, and signs of systemic discomfort like weight loss and lethargy. The application may contribute to improved nutrient uptake and supports the stabilization of the patient's body condition.

The product is considered relevant for use within routine parasite control programs, which is applied in clinical settings that involve acute or unstable symptom patterns. This use contributes to easing the overall symptom load for both clinical worm infestations and asymptomatic infections.

Quick Fact: Relief for Parasite Symptoms
Symptom Domains Gastrointestinal distress, systemic decline, functional strain
Condition Categories Mixed parasitic infections (cestodes/nematodes), acute symptomatic episodes
Primary Benefit Supportive relief, stabilization of body condition
Usage Context Routine control, clinical intervention

Eligibility and Restrictions for Use

Zantel (albendazole) eligibility is defined by official regulatory documentation and is strictly based on age, reproductive status, and pre-existing medical conditions.

Contraindications and Restricted Use

Classification Population/Condition
Contraindicated Women who are pregnant or suspected of being pregnant.
Contraindicated Patients with known hypersensitivity to albendazole or its components.
Restricted Use Women of childbearing age must use effective contraception during and for a period after treatment, and should initiate therapy only after a negative pregnancy test.

Age and Condition-Specific Eligibility

  • Pediatric Use: The medicine is generally not recommended for children under two years of age for most indications, and use in children under six years for systemic infections is limited. However, specific single-dose regimens are allowed for children aged 1–2 years for certain intestinal parasites.
  • Hepatic Impairment: Patients with pre-existing liver disease must use Zantel with caution, as it is metabolized by the liver. Close monitoring of liver enzymes is required.
  • Lactation: Use during breastfeeding is generally discouraged unless the potential benefit outweighs the unknown risk, as it is unknown if the drug or its metabolites are secreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products for Zantel (Albendazole)

Official regulatory information for Zantel focuses on pharmacokinetic interactions that significantly alter the plasma concentration of its active metabolite, Albendazole sulfoxide.

Pharmacokinetic Interactions

Co-administration with several medicinal products can increase or decrease the exposure of Zantel's active component. These interactions primarily involve the Cytochrome P450 (CYP450) enzyme system, which metabolizes the drug.

Classification Interacting Substances/Products Effect on Albendazole Sulfoxide Exposure
Exposure-Enhancing Praziquantel, Dexamethasone, Cimetidine, Grapefruit Juice Increases C max and AUC (e.g., Dexamethasone by 56%, Praziquantel by 50%)
Exposure-Reducing Phenytoin, Phenobarbital, Carbamazepine, Rifampin Decreases plasma concentration

Administration Requirements

Official labeling includes a mandatory requirement for administration. Zantel must be taken with food to enhance the absorption of the active metabolite, ensuring adequate drug availability.

Population-Specific Notes

Patients with hepatic disease or echinococcosis require more frequent monitoring of blood counts due to the potential for increased systemic exposure and toxicity, a consideration tied to the drug's metabolism.

Mechanism of Action

Zantel (albendazole) is a benzimidazole anthelmintic that acts by binding to beta-tubulin in susceptible helminths. This binding occurs specifically at the colchicine-sensitive site, which subsequently prevents the polymerization of alpha-tubulin and beta-tubulin dimers into microtubules.

Inhibition of Microtubule Polymerization

This molecular interaction causes the collapse of essential cellular structures required for the maintenance of helminth cell shape, nutrient transport, and motility. The loss of microtubule integrity results in significant ultrastructural alterations within the intestinal cells and the tegument of the helminth.

Metabolic Cascade and Energy Deprivation

The altered cellular architecture leads to a subsequent inhibition of glucose uptake across the larval and adult stages of the parasite. This modification to the cellular pathway depletes the parasite's internal glycogen reserves. The resulting impairment of glucose utilization and subsequent reduction in Adenosine Triphosphate (ATP) production causes a progressive loss of systemic energy, leading to the cessation of motility and biological function.

Dosage and Administration Information

How to Use Zantel

This section outlines the administration instructions for the Zantel (Fenbendazole/Praziquantel) oral tablet and focuses strictly on procedural patterns of use.


Administration Scope

The medicine is designated for oral administration only. The instructions require that the patient's body weight must be determined as accurately as possible to ensure the correct dose is administered. Administration may occur either directly or by mixing the tablet with the daily diet or a portion of meat; fasting is not necessary prior to treatment.

Feature Official Instruction
Route of administration Oral administration only.
Dosing schedule Standard dose is 5 mg/kg Praziquantel and 50 mg/kg Fenbendazole per dose.
Timing in relation to meals Fasting is not necessary; can be administered with food.
Special procedural conditions Body weight must be accurately determined. Part used tablets must be discarded.

Regimen Duration and Population Adjustments

Usage patterns vary significantly depending on the clinical scenario, necessitating either a single dose or a consecutive course.

For routine control, the standard dose is administered as a single treatment, typically repeated once every three months. For the treatment of clinical worm infestations, the standard dose is administered daily for a short consecutive course of two or three days, depending on the species and condition. Unweaned young (puppies/kittens under 12 weeks) follow a specialized pattern, receiving the standard dose daily for three consecutive days, with the course repeated at 2 weekly intervals from age of two weeks. The instructions note that the stated dose for pregnant animals must not be exceeded.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zantel

Evidence for Use in Mixed Parasitic Infections (Roundworms and Tapeworms)

The Fenbendazole-Praziquantel combination has been studied for its relevance in managing mixed parasitic infections, which involve both roundworms (nematodes) and tapeworms (cestodes). Research in this area primarily includes independent reviews and regulatory documentation, rather than product-specific randomized clinical trials (RCTs). These studies examine the strategic advantage of combining two active ingredients to evaluate outcomes related to parasite clearance across major parasite classes.

Evidence for Use in Clinical Worm Infestations and Symptomatic Episodes

Zantel was evaluated in contexts where the host animal showed clinical worm infestations or episodic symptom patterns associated with a parasitic burden. The evidence comes primarily from regulatory documents and observations made in clinical settings where symptoms like chronic diarrhea, vomiting, lethargy, or weight loss were studied for change.

Evidence for Use in Routine Deworming Programs and Asymptomatic Cases

The Fenbendazole-Praziquantel combination was studied for its relevance within routine deworming programs. Evidence, including independent reviews, describes patterns related to the approach of addressing the management of roundworms and tapeworms simultaneously. The application in asymptomatic cases was studied for its role in evaluating outcomes related to preventing the manifestation of symptoms.

What Is Still Uncertain About Zantel's Research Base

The research on Zantel and its combination of active ingredients is ongoing, and several areas remain uncertain or under-characterized. Limited information for long-term outcomes is a significant gap, as most available evidence focuses on short-term clearance and symptom response.

Furthermore, specific trials (RCTs) directly on the product combination are not explicitly cited in the high-level summaries. Comparative evidence is lacking regarding Zantel's performance against other specific dual-agent anthelmintics or monotherapies. The research provides context but does not predict individual outcomes.

Key Studies & References Zantel regulatory document (Irish Health Products Regulatory Authority - HPRA)

Frequently Asked Questions (FAQ)

Common questions about Zantel (FAQ)


Q: What should I do if I forget to take my Zantel dose?

A: Official patient counseling outlines a procedure where a missed dose can be taken if remembered soon; otherwise, if it is nearly time for the next dose, the missed dose should be skipped. Taking a double dose is not advised.


Q: Is it normal to feel dizzy when first starting Zantel?

A: Official product information states that dizziness or vertigo are commonly reported side effects. Regulatory information suggests that being aware of potential dizziness is prudent, especially when initiating treatment.


Q: How long does it usually take before I can tell if Zantel is working?

A: The time frame for the drug to work is closely tied to the specific treatment regimen being used. The prescribed cycles vary widely, ranging from a single dose up to regimens of several months, which dictates the expected time for parasite clearance.


Q: Can Zantel affect my sleep patterns?

A: While not directly related to sleep, official documentation lists nervous system side effects such as dizziness and lethargy. These types of effects may potentially impact alertness and disrupt normal rest patterns.


Q: What foods or drinks should be avoided while taking Zantel?

A: According to the official product information, Zantel should be taken with food to help the body absorb it effectively. Patients are specifically advised to avoid consuming grapefruit or grapefruit juice while taking this medication.


Q: Does Zantel have a 'black box' warning from the FDA?

A: The official label contains prominent, bolded WARNINGS concerning the potential for fatal bone marrow suppression and embryo-fetal toxicity. These warnings emphasize the need for close monitoring during treatment.


Q: Does Zantel interact with birth control pills?

A: Regulatory guidance indicates that effective contraception is necessary for females who can become pregnant during treatment and for a required period after the last dose. This precaution is in place due to the risk of fetal harm.


Q: Is Zantel safe for older adults (seniors)?

A: Regulatory documents include studies on how the drug is processed in both pediatric and older adult populations. While these processes are generally similar to those in younger adults, the use of Zantel in children under two years of age is limited for many conditions.


Q: Can Zantel cause problems with my kidneys or liver?

A: Official safety documents show the drug is associated with increases in liver enzymes and requires close monitoring for patients with existing liver disease. While it is processed by the liver, the drug's elimination by the kidneys is considered minimal.


Q: What is the purpose of the different strengths of Zantel tablets?

A: The drug is typically supplied as a single standard strength tablet. The overall dose is determined based on the patient's body weight and the specific condition being treated, rather than choosing between multiple different tablet strengths.


Q: How long does Zantel stay in my system after the last dose?

A: The active component, albendazole sulfoxide, has an elimination half-life of approximately 8.5 hours, which is the time it takes for half of the drug to be removed from the system.


Q: What should I tell my doctor before starting Zantel?

A: Before starting this medication, it is important to provide your healthcare professional with a complete medical history. Official documentation specifies that conditions such as liver disease, blood disorders, eye problems, and pregnancy status are relevant factors that should be discussed with the prescribing professional.


Q: Are there any known drug interactions that are considered serious with Zantel?

A: Official documents describe interactions with certain medications, such as Praziquantel or Cimetidine, that can increase the amount of Zantel's active component in the body. These pharmacokinetic interactions necessitate close monitoring during co-administration.


Q: Can Zantel cause skin rashes or itching?

A: Skin reactions like rashes, itching (pruritus), and hives (urticaria) are listed as potential side effects. These effects are tracked as hypersensitivity responses.


Q: Where can I find the official patient information leaflet for Zantel?

A: The most authoritative patient information is contained in the FDA's Full Prescribing Information. This document includes a dedicated Patient Counseling Information section intended for patient guidance.


Q: What does 'contraindicated' mean in relation to Zantel?

A: When a condition is listed as 'contraindicated,' it means that the drug must not be used because the risks outweigh the benefits. For Zantel, this restriction applies if a patient has a known hypersensitivity to the drug or its components.


Q: How is Zantel processed by the body (metabolism)?

A: Zantel is quickly changed by the liver into its active component, albendazole sulfoxide, which then performs the drug's function. This active component has an elimination half-life of approximately 8.5 hours, which is the time it takes for half of the drug to be removed from the system.


Q: Can Zantel affect my ability to drive or operate machinery?

A: Because the medication may cause side effects like dizziness or reduced alertness, official patient counseling advises caution. Activities such as driving or operating machinery should be avoided until the individual is aware of how the drug may affect their coordination and focus.


Q: Do studies show Zantel works well in all age groups?

A: Regulatory documents include studies on how the drug is processed in both pediatric and older adult populations. While these processes are generally similar to those in younger adults, the use of Zantel in children under two years of age is limited for many conditions.


Q: Are there specific symptoms that Zantel is NOT intended to treat?

A: Zantel is a specialized anthelmintic medication indicated solely for the treatment of specific parasitic worm infections. It is not intended for use in treating general symptoms or conditions that are unrelated to parasitic infections.


Q: Is Zantel a controlled substance?

A: Regulatory classification confirms that Zantel is not a controlled substance.

How should Zantel be stored and disposed of?

How to Store and Dispose of Zantel?

Zantel (fenbendazole/praziquantel) storage and disposal must strictly follow regulatory documentation to ensure product stability and safety.


Official Storage Conditions

The product does not require any special storage conditions beyond maintaining it in a cool dry place. The tablets must be kept out of the reach of children, uninformed persons, and animals.

Stability Constraint Requirement
Shelf-Life Up to 4 years as packaged for sale.
Part-Used Doses Discard part-used tablets immediately after dosing.

Disposal and Handling

All unused product and waste material must be disposed of in accordance with local requirements. The product should not be allowed to enter surface waters due to its harmful effects on aquatic organisms. Additionally, individuals must wash hands after handling the tablets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zantel found in:

A-Z Index: